Commentary
Extended Survival With PARP Inhibitors Changes Expectations in Metastatic Breast Cancer
Clifford Hudis: Extended Survival With PARP Inhibitors Changes Expectations in Metastatic Breast Cancer
Extended Survival With PARP Inhibitors Changes Expectations in Metastatic Breast Cancer
Dr. Clifford A. Hudis is Chief, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer, New York, NY. View profile. 1. In your view, which development in breast cancer that has occurred in 2009 could have the most significant impact on oncology?One development in breast cancer that may have broad and quite exciting implications is the development of safe and effective inhibitors of the PARP enzyme. The poly ADP-ribose polymerase, or PARP, enzyme is an enzyme that plays a critical role...
